First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

Researchers at the University of Tsukuba have investigated the changes in the primary evaluation items in phase II clinical ...

Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about ...

The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States and a top ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...